Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × pCR Rate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7157 Neoplasms 4487 Prostatic Neoplasms 3456 Colorectal Neoplasms 2901 Carcinoma, Non-Small-Cell Lung 2796 Lung Neoplasms 2505 Leukemia, Myeloid, Acute 1955 Pancreatic Neoplasms 1852 Multiple Myeloma 1794 Carcinoma, Hepatocellular 1709 Neoplasm Metastasis 1575 Stomach Neoplasms 1481 Lymphoma 1448 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1428 Head and Neck Neoplasms 1415 Brain Neoplasms 1358 Melanoma 1336 Ovarian Neoplasms 1330 Leukemia 1299 Rectal Neoplasms 1255 Recurrence 1241 Colonic Neoplasms 1195 Glioblastoma 1120 Uterine Cervical Neoplasms 1073 Lymphoma, Non-Hodgkin 1063 Leukemia, Lymphocytic, Chronic, B-Cell 987 Esophageal Neoplasms 958 Lymphoma, Large B-Cell, Diffuse 927 Lymphoma, Follicular 927 Squamous Cell Carcinoma of Head and Neck 904

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡